CDH13
Basic information
Region (hg38): 16:82626965-83800640
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CDH13 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 12 | 20 | ||||
missense | 48 | 57 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 6 | 2 | 8 | |||
non coding | 44 | 45 | ||||
Total | 0 | 0 | 50 | 21 | 53 |
Variants in CDH13
This is a list of pathogenic ClinVar variants found in the CDH13 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-82627104-A-G | not specified | Likely benign (May 24, 2023) | ||
16-82627107-T-G | not specified | Likely benign (Apr 12, 2024) | ||
16-82627118-T-C | not specified | Uncertain significance (Aug 30, 2021) | ||
16-82627145-A-G | CDH13-related disorder | Likely benign (Feb 19, 2019) | ||
16-82627349-T-C | Benign (Jun 21, 2021) | |||
16-82639442-C-T | not specified | Benign (-) | ||
16-82639464-A-G | CDH13-related disorder | Benign (Jun 05, 2020) | ||
16-82639485-T-G | not specified | Benign (-) | ||
16-82858053-A-G | Benign (Jun 18, 2021) | |||
16-82858291-G-A | Benign (Jun 18, 2021) | |||
16-82858377-T-C | not specified | Uncertain significance (Jun 18, 2024) | ||
16-82858425-C-A | not specified | Uncertain significance (Jan 24, 2023) | ||
16-82858432-A-G | not specified | Benign (Jun 10, 2021) | ||
16-82858467-C-G | not specified | Uncertain significance (Jun 18, 2021) | ||
16-83031764-G-C | Benign (Jun 18, 2021) | |||
16-83031798-T-C | Benign (Jun 18, 2021) | |||
16-83031886-G-C | Benign (Jun 18, 2021) | |||
16-83032046-G-A | not specified | Likely benign (Mar 20, 2023) | ||
16-83032058-C-G | not specified | Uncertain significance (Jan 17, 2024) | ||
16-83032059-G-A | not specified | Benign (-) | ||
16-83032085-A-T | not specified | Uncertain significance (May 26, 2023) | ||
16-83032090-G-A | not specified | Likely benign (Dec 28, 2022) | ||
16-83032111-A-T | not specified | Uncertain significance (Sep 27, 2022) | ||
16-83032118-C-T | not specified | Uncertain significance (Apr 20, 2023) | ||
16-83032124-GC-G | CDH13-related disorder | Uncertain significance (Jun 16, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CDH13 | protein_coding | protein_coding | ENST00000268613 | 15 | 1169797 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000706 | 0.999 | 124641 | 0 | 13 | 124654 | 0.0000521 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.533 | 480 | 448 | 1.07 | 0.0000253 | 4971 |
Missense in Polyphen | 125 | 177.7 | 0.70344 | 1989 | ||
Synonymous | -5.05 | 268 | 181 | 1.48 | 0.0000114 | 1525 |
Loss of Function | 3.29 | 11 | 30.7 | 0.359 | 0.00000148 | 371 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000693 | 0.0000646 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000464 | 0.0000464 |
European (Non-Finnish) | 0.0000998 | 0.0000973 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. May act as a negative regulator of neural cell growth. {ECO:0000269|PubMed:10737605}.;
- Pathway
- Pathways in clear cell renal cell carcinoma;Cell-cell junction organization;Adherens junctions interactions;Cell junction organization;Cell-Cell communication
(Consensus)
Recessive Scores
- pRec
- 0.403
Intolerance Scores
- loftool
- 0.493
- rvis_EVS
- 0.31
- rvis_percentile_EVS
- 72.23
Haploinsufficiency Scores
- pHI
- 0.320
- hipred
- Y
- hipred_score
- 0.554
- ghis
- 0.525
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0882
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cdh13
- Phenotype
- endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype;
Gene ontology
- Biological process
- mitotic cell cycle;cell morphogenesis;positive regulation of endothelial cell proliferation;positive regulation of cell-matrix adhesion;sprouting angiogenesis;cell-cell junction assembly;homophilic cell adhesion via plasma membrane adhesion molecules;negative regulation of cell adhesion;Rho protein signal transduction;negative regulation of cell population proliferation;calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules;Rac protein signal transduction;lamellipodium assembly;regulation of endocytosis;positive regulation of cell migration;adherens junction organization;regulation of epidermal growth factor receptor signaling pathway;endothelial cell migration;keratinocyte proliferation;cell-cell adhesion mediated by cadherin;positive regulation of transcription by RNA polymerase II;positive regulation of smooth muscle cell proliferation;positive regulation of calcium-mediated signaling;positive regulation of positive chemotaxis;localization within membrane;low-density lipoprotein particle mediated signaling;cell-cell adhesion
- Cellular component
- extracellular region;extracellular space;cytoplasm;plasma membrane;caveola;cell-cell adherens junction;focal adhesion;external side of plasma membrane;cell surface;catenin complex;anchored component of membrane;neuron projection;perinuclear region of cytoplasm;collagen-containing extracellular matrix;extracellular exosome;GABA-ergic synapse
- Molecular function
- calcium ion binding;cytoskeletal protein binding;low-density lipoprotein particle binding;protein homodimerization activity;cadherin binding;adiponectin binding;lipoprotein particle binding